| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/23/2002 | CA2428647A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 05/23/2002 | CA2428519A1 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists |
| 05/23/2002 | CA2428350A1 Slo2 and slo4, novel potassium channel proteins from human brain |
| 05/23/2002 | CA2428249A1 Combination therapy for estrogen-dependent disorders |
| 05/23/2002 | CA2427010A1 Transporters and ion channels |
| 05/23/2002 | CA2426521A1 Treatment of sexual dysfunction using bombesin antagonist |
| 05/23/2002 | CA2426069A1 Treatment of anxiety disorders |
| 05/23/2002 | CA2425117A1 Dibenzoxazepine alpha v integrin receptor antagonist |
| 05/22/2002 | EP1206942A1 Water channel opener compositions and medicinal compositions for ophthalmic use |
| 05/22/2002 | EP1206930A2 An oral treatment/care agent |
| 05/22/2002 | EP1206582A1 Methods and compositions for inhibition of membrane fusion-associated events, including hiv transmission |
| 05/22/2002 | EP1206581A2 Methods of identifying anti-viral agents |
| 05/22/2002 | EP1206569A2 Method of screening for triacyglycerol hydrolase inhibitors |
| 05/22/2002 | EP1206562A2 Genetically engineered cell lines, and their uses, in particular for neurotoxicity testing |
| 05/22/2002 | EP1206553A2 Isomerase proteins |
| 05/22/2002 | EP1206543A2 Membrane associated proteins |
| 05/22/2002 | EP1206541A1 Dendritic enriched secreted lymphocyte activation molecule |
| 05/22/2002 | EP1206529A2 UDP-N-ACETYLGLUCOSAMINE: GALACTOSE-BETA 1,3-N-ACETYLGALACTOSAMINE-ALPHA-R/(GlcNAc to GalNAc) BETA 1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2GnT3 |
| 05/22/2002 | EP1206285A2 Drug-carrier complexes and methods of use thereof |
| 05/22/2002 | EP1206276A2 Tissue volume reduction |
| 05/22/2002 | EP1206274A2 Use of interleukin-18 inhibitors to inhibit tumor metastasis |
| 05/22/2002 | EP1206273A2 Peptides that block viral infectivity and methods of use thereof |
| 05/22/2002 | EP1206270A1 Ceramide and chemotherapeutic agents for inducing cell death |
| 05/22/2002 | EP1206269A1 Compositions and methods for the treatment of skin disorders |
| 05/22/2002 | EP1206266A2 Formulations for parenteral use of estramustine phosphate and albumin |
| 05/22/2002 | EP1206265A1 Src kinase inhibitor compounds |
| 05/22/2002 | EP1206264A2 Compositions and methods for treating opiate intolerance |
| 05/22/2002 | EP1206261A2 Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases |
| 05/22/2002 | EP1206259A2 Use of substance p antagonists for the treatment of adenocarcinoma |
| 05/22/2002 | EP1206258A1 Compositions containig esthers for treating parasitic infestations of organisms |
| 05/22/2002 | EP1206256A2 Combination therapy using pentafluorobenzenesulfonamide and platin compound |
| 05/22/2002 | EP1206251A1 Amplification of folate-mediated targeting to tumor cells using nanoparticles |
| 05/22/2002 | EP1206245A2 Phospholipid gel |
| 05/22/2002 | EP1206234A2 Methods and compositions for modulating cell proliferation and cell death |
| 05/22/2002 | EP1152776B1 Biodegradable, injectable oligomer-polymer composition |
| 05/22/2002 | EP1014940B1 Ophthalmic composition including a cationic glycoside and an anionic therapeutic agent |
| 05/22/2002 | CN1350540A Process for preparing amine platinum complexes |
| 05/22/2002 | CN1350466A A combination of FBPase Inhibitors and insulin sensitizers for the treatment of diabetes |
| 05/22/2002 | CN1350465A Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetiques |
| 05/22/2002 | CN1350463A A Pharmaceutical formulation containing an inhibitor of carboxypeptidase U and a thrombin inhibitor |
| 05/22/2002 | CN1350445A Treatment of hepatitis C using hyperthermia |
| 05/22/2002 | CN1350435A A composition containing carvacrol and thymol for use as abactericide |
| 05/21/2002 | US6392028 Functional DNA clone for hepatitis C virus (HCV) and uses thereof |
| 05/21/2002 | US6391922 Administering neurotransmitter |
| 05/21/2002 | US6391920 Administering hormone inhibitor; stimulant of testosterone |
| 05/21/2002 | US6391919 Aids therapy |
| 05/21/2002 | US6391910 Opioid antagonist; analgesic |
| 05/21/2002 | US6391879 Therapeutic anti-fungal nail preparation |
| 05/21/2002 | US6391870 Dopaminergic agent |
| 05/21/2002 | US6391865 Aids therapy; antiinflammatory agents; rheumatic diseases; skin disorders |
| 05/21/2002 | US6391864 Glucosamine mixtures |
| 05/21/2002 | US6391859 [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides |
| 05/21/2002 | US6391856 Method for treatment of allergic reaction using formyl peptide |
| 05/21/2002 | US6391606 Peptides; for use in the develoment of human diagnostic and therapeutic agents |
| 05/21/2002 | US6391580 Ras proteins |
| 05/21/2002 | US6391543 Screening sample for preferential nucleotide sequences; incubate sample with nucleotide sequences, monitor sample for signal indicating bound nucleotide sequences |
| 05/21/2002 | US6390821 Phosphorylation |
| 05/21/2002 | CA2215745C Human stat4 |
| 05/21/2002 | CA1341359C Manufacturing process for a single-cell lifeform killing or growth inhibiting composition containing fluorine (f-) and lithium (li+) |
| 05/16/2002 | WO2002039121A2 Methods for detecting the efficacy of anticancer treatments |
| 05/16/2002 | WO2002039117A1 Methods for the treatment of cellular proliferative disorders |
| 05/16/2002 | WO2002038807A1 Method for screening agents capable of treating obesity |
| 05/16/2002 | WO2002038797A2 Modulators of bruton's tyrosine kinase, their identification and use |
| 05/16/2002 | WO2002038778A1 Differentiation-inducing substances |
| 05/16/2002 | WO2002038744A2 Proteases |
| 05/16/2002 | WO2002038732A2 Human testis specific serine/threonine kinase |
| 05/16/2002 | WO2002038730A2 Novel human potassium channel beta subunit |
| 05/16/2002 | WO2002038607A2 A 'bach' g protein coupled receptor polypeptide and polynucleotide encoding this receptor |
| 05/16/2002 | WO2002038561A1 Indolylmaleimide derivatives as protein kinase c inhibitors |
| 05/16/2002 | WO2002038534A2 Substituted alkyldiamines as inhibitors of plasmepsin or related proteases |
| 05/16/2002 | WO2002038186A1 Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides |
| 05/16/2002 | WO2002038181A2 Synergistic medicament containing aromatic agents and having an antagonistic, regenerative and/or protagonist decontamination effect |
| 05/16/2002 | WO2002038169A1 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 05/16/2002 | WO2002038168A2 Use of selectin-binding active ingredients for the treatment of inflammatory and tumoral diseases |
| 05/16/2002 | WO2002038160A1 Method for the treatment of inflammation |
| 05/16/2002 | WO2002038158A1 Improved treatment |
| 05/16/2002 | WO2002038143A2 Enhanced efficacy and safety of genotoxic therapy by p38 mapk modulation |
| 05/16/2002 | WO2002038142A2 Serotonergic compositions and methods for treatment of mild cognitive impairment |
| 05/16/2002 | WO2002038141A2 Compositions and methods for treatment of mild cognitive impairment |
| 05/16/2002 | WO2002038140A2 Therapeutic uses for ip3 receptor-mediated calcium channel modulators |
| 05/16/2002 | WO2002038133A2 Compositions containing hydrolytically unstable compounds |
| 05/16/2002 | WO2002038129A2 Delayed-release pharmaceutical formulations containing proinsulin c-peptide |
| 05/16/2002 | WO2002038108A2 Methods of treating disorders related to apoe |
| 05/16/2002 | WO2002038107A2 Stat modulators |
| 05/16/2002 | WO2002038106A2 Calcilytic compounds |
| 05/16/2002 | WO2002038035A2 Methods for inhibiting pain |
| 05/16/2002 | WO2002037968A1 Methods for treating disorders of neuronal deficiency with bone marrow-derived cells |
| 05/16/2002 | WO2002037937A2 Acid derivatives useful as serine protease inhibitors |
| 05/16/2002 | WO2002020488A3 Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor |
| 05/16/2002 | WO2002020026A3 Treatment of drug resistant organisms with nitric oxide |
| 05/16/2002 | WO2002020003A3 Use of carp inhibitors for the treatment of heart diseases |
| 05/16/2002 | WO2002018448A3 Percarboxylated polysaccharides, and a process for their preparation |
| 05/16/2002 | WO2002017930A3 Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| 05/16/2002 | WO2002007770A3 Polymeric conjugates of antitumor agents |
| 05/16/2002 | WO2002003971A3 Pharmaceutical composition and method for the treatment of retroviral infections |
| 05/16/2002 | WO2002000218A3 Methods of treating neutrophil-related diseases with topical anesthetics |
| 05/16/2002 | WO2001098291A3 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| 05/16/2002 | WO2001097790A3 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents |
| 05/16/2002 | WO2001097789A3 Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoisomerase i and ii inhibitors |
| 05/16/2002 | WO2001092496A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |